Maternal Serum B Cell activating factor in hypertensive and normotensive pregnancies

J. Tay, A. Costanzi, K. Basello, G. Piuri, E. Ferrazzi, A. F. Speciani, C. C. Lees

Research output: Contribution to journalArticle

Abstract

Objectives: The objective of this study was the analysis of B-Cell Activating Factor (BAFF) levels in pregnancies affected by PE, and in pregnancies affected by fetal growth restriction without Hypertensive disorders and its possible correlation with pulse wave velocity and cardiac output. Study design: Prospective study of 69 women at 24–40 weeks gestation. Haemodynamic function was assessed in those with Pre-eclampsia (PE, n = 19), fetal growth restriction (FGR, n = 10) and healthy pregnancies (n = 40). Maternal venous BAFF levels at recruitment were measured using ELISA. We analysed the relationship between BAFF and cardiac output (CO), and BAFF and PWV (pulse wave velocity); the gold standard for assessing arterial stiffness. PWV was measured with an oscillometric device and CO using inert gas rebreathing technique. PWV and CO were converted to gestation adjusted indices (z scores). Main outcome measures: The association between BAFF levels in PE and FGR, and the relationship of BAFF with PWV and CO. Results: BAFF was higher in PE (p = 0.03) but not in FGR (p = 0.83) when compared to healthy pregnancies. There was a positive correlation between BAFF levels and z score PWV (r = 0.25, p = 0.04), but not CO (r = −0.01, p = 0.91). BAFF levels did not change with gestational age. (r = 0.012, p = 0.925). Conclusions: These findings provide evidence of a possible contribution of BAFF to both maternal inflammation and arterial dysfunction associated with PE. Though no relationship was found with another disorder of placentation: normotensive FGR, this condition is not thought to be associated with maternal inflammation.

Original languageEnglish
Pages (from-to)58-61
Number of pages4
JournalPregnancy Hypertension
Volume13
DOIs
Publication statusPublished - Jul 1 2018

Fingerprint

B-Cell Activating Factor
Pulse Wave Analysis
Cardiac Output
Mothers
Pregnancy
Serum
Fetal Development
Noble Gases
Placentation
Arteritis
Vascular Stiffness
Pre-Eclampsia
Gestational Age
Hemodynamics
Enzyme-Linked Immunosorbent Assay
Outcome Assessment (Health Care)
Prospective Studies
Inflammation
Equipment and Supplies

Keywords

  • Arterial function
  • BAFF
  • Fetal growth restriction
  • Pre-eclampsia
  • Pulse wave velocity

ASJC Scopus subject areas

  • Internal Medicine
  • Obstetrics and Gynaecology

Cite this

Maternal Serum B Cell activating factor in hypertensive and normotensive pregnancies. / Tay, J.; Costanzi, A.; Basello, K.; Piuri, G.; Ferrazzi, E.; Speciani, A. F.; Lees, C. C.

In: Pregnancy Hypertension, Vol. 13, 01.07.2018, p. 58-61.

Research output: Contribution to journalArticle

Tay, J. ; Costanzi, A. ; Basello, K. ; Piuri, G. ; Ferrazzi, E. ; Speciani, A. F. ; Lees, C. C. / Maternal Serum B Cell activating factor in hypertensive and normotensive pregnancies. In: Pregnancy Hypertension. 2018 ; Vol. 13. pp. 58-61.
@article{c6b3940f4b1e440a8ac5a35a27947b28,
title = "Maternal Serum B Cell activating factor in hypertensive and normotensive pregnancies",
abstract = "Objectives: The objective of this study was the analysis of B-Cell Activating Factor (BAFF) levels in pregnancies affected by PE, and in pregnancies affected by fetal growth restriction without Hypertensive disorders and its possible correlation with pulse wave velocity and cardiac output. Study design: Prospective study of 69 women at 24–40 weeks gestation. Haemodynamic function was assessed in those with Pre-eclampsia (PE, n = 19), fetal growth restriction (FGR, n = 10) and healthy pregnancies (n = 40). Maternal venous BAFF levels at recruitment were measured using ELISA. We analysed the relationship between BAFF and cardiac output (CO), and BAFF and PWV (pulse wave velocity); the gold standard for assessing arterial stiffness. PWV was measured with an oscillometric device and CO using inert gas rebreathing technique. PWV and CO were converted to gestation adjusted indices (z scores). Main outcome measures: The association between BAFF levels in PE and FGR, and the relationship of BAFF with PWV and CO. Results: BAFF was higher in PE (p = 0.03) but not in FGR (p = 0.83) when compared to healthy pregnancies. There was a positive correlation between BAFF levels and z score PWV (r = 0.25, p = 0.04), but not CO (r = −0.01, p = 0.91). BAFF levels did not change with gestational age. (r = 0.012, p = 0.925). Conclusions: These findings provide evidence of a possible contribution of BAFF to both maternal inflammation and arterial dysfunction associated with PE. Though no relationship was found with another disorder of placentation: normotensive FGR, this condition is not thought to be associated with maternal inflammation.",
keywords = "Arterial function, BAFF, Fetal growth restriction, Pre-eclampsia, Pulse wave velocity",
author = "J. Tay and A. Costanzi and K. Basello and G. Piuri and E. Ferrazzi and Speciani, {A. F.} and Lees, {C. C.}",
year = "2018",
month = "7",
day = "1",
doi = "10.1016/j.preghy.2018.05.001",
language = "English",
volume = "13",
pages = "58--61",
journal = "Pregnancy Hypertension",
issn = "2210-7789",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Maternal Serum B Cell activating factor in hypertensive and normotensive pregnancies

AU - Tay, J.

AU - Costanzi, A.

AU - Basello, K.

AU - Piuri, G.

AU - Ferrazzi, E.

AU - Speciani, A. F.

AU - Lees, C. C.

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Objectives: The objective of this study was the analysis of B-Cell Activating Factor (BAFF) levels in pregnancies affected by PE, and in pregnancies affected by fetal growth restriction without Hypertensive disorders and its possible correlation with pulse wave velocity and cardiac output. Study design: Prospective study of 69 women at 24–40 weeks gestation. Haemodynamic function was assessed in those with Pre-eclampsia (PE, n = 19), fetal growth restriction (FGR, n = 10) and healthy pregnancies (n = 40). Maternal venous BAFF levels at recruitment were measured using ELISA. We analysed the relationship between BAFF and cardiac output (CO), and BAFF and PWV (pulse wave velocity); the gold standard for assessing arterial stiffness. PWV was measured with an oscillometric device and CO using inert gas rebreathing technique. PWV and CO were converted to gestation adjusted indices (z scores). Main outcome measures: The association between BAFF levels in PE and FGR, and the relationship of BAFF with PWV and CO. Results: BAFF was higher in PE (p = 0.03) but not in FGR (p = 0.83) when compared to healthy pregnancies. There was a positive correlation between BAFF levels and z score PWV (r = 0.25, p = 0.04), but not CO (r = −0.01, p = 0.91). BAFF levels did not change with gestational age. (r = 0.012, p = 0.925). Conclusions: These findings provide evidence of a possible contribution of BAFF to both maternal inflammation and arterial dysfunction associated with PE. Though no relationship was found with another disorder of placentation: normotensive FGR, this condition is not thought to be associated with maternal inflammation.

AB - Objectives: The objective of this study was the analysis of B-Cell Activating Factor (BAFF) levels in pregnancies affected by PE, and in pregnancies affected by fetal growth restriction without Hypertensive disorders and its possible correlation with pulse wave velocity and cardiac output. Study design: Prospective study of 69 women at 24–40 weeks gestation. Haemodynamic function was assessed in those with Pre-eclampsia (PE, n = 19), fetal growth restriction (FGR, n = 10) and healthy pregnancies (n = 40). Maternal venous BAFF levels at recruitment were measured using ELISA. We analysed the relationship between BAFF and cardiac output (CO), and BAFF and PWV (pulse wave velocity); the gold standard for assessing arterial stiffness. PWV was measured with an oscillometric device and CO using inert gas rebreathing technique. PWV and CO were converted to gestation adjusted indices (z scores). Main outcome measures: The association between BAFF levels in PE and FGR, and the relationship of BAFF with PWV and CO. Results: BAFF was higher in PE (p = 0.03) but not in FGR (p = 0.83) when compared to healthy pregnancies. There was a positive correlation between BAFF levels and z score PWV (r = 0.25, p = 0.04), but not CO (r = −0.01, p = 0.91). BAFF levels did not change with gestational age. (r = 0.012, p = 0.925). Conclusions: These findings provide evidence of a possible contribution of BAFF to both maternal inflammation and arterial dysfunction associated with PE. Though no relationship was found with another disorder of placentation: normotensive FGR, this condition is not thought to be associated with maternal inflammation.

KW - Arterial function

KW - BAFF

KW - Fetal growth restriction

KW - Pre-eclampsia

KW - Pulse wave velocity

UR - http://www.scopus.com/inward/record.url?scp=85047005161&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047005161&partnerID=8YFLogxK

U2 - 10.1016/j.preghy.2018.05.001

DO - 10.1016/j.preghy.2018.05.001

M3 - Article

AN - SCOPUS:85047005161

VL - 13

SP - 58

EP - 61

JO - Pregnancy Hypertension

JF - Pregnancy Hypertension

SN - 2210-7789

ER -